Introduction {#s1}
============

The intestinal microbiota has been shown to critically influence a multitude of host physiological functions, often through modulation of the immune system ([@bib17]; [@bib28]). Evidence includes studies in germ-free mice, which show that both pro-inflammatory T-helper 17 (T~h~17) cells and anti-inflammatory regulatory T-cells (T~reg~) are reduced in numbers in the intestinal lamina propria relative to conventional or specific pathogen-free mice ([@bib2]), and that repopulation with specific bacteria can reconstitute them ([@bib4]; [@bib21]). One route to how the microbiota influences immune system activation is by the production of small molecules ([@bib11]). Microbially produced short-chain fatty acids (SCFAs) were shown to facilitate extrathymic differentiation of immune system modulatory T~reg~ ([@bib1]; [@bib5]; [@bib32]) and are implicated in T~reg~-dependent anti-inflammatory properties of a mix of 17 human-derived Clostridia strains ([@bib5]; [@bib36]). Interestingly, individual Clostridia strains only have a modest effect on T~reg~ induction -- optimal induction relies on the synergistic interplay of several strains ([@bib5]; [@bib6]). Because of these properties, there is currently great interest in the manipulation of this community for the treatment of inflammatory and allergic diseases ([@bib20]; [@bib26]; [@bib38]). Efforts involving transplantation of bacteria from healthy humans to humans with *C. difficile* infections or with metabolic diseases have provided evidence that microbiota repopulation could be used as possible strategy for disease prevention and treatment ([@bib37]; [@bib39]). For this reason, intestinal supplementation of defined compositions of gut bacteria to treat a range of diseases is currently being pursued by multiple bio-pharmaceutical companies ([@bib13]). Determining what microbial consortia can colonize the host and stably coexist with an already resident microbial community, while inducing the desired immune response, is still a major challenge that hinders the translation of these efforts into the clinic ([@bib22]; [@bib41]).

In previous work, some of us identified a set of 17 potent T~reg~-inducing Clostridia strains to select candidate subsets from ([@bib5]). The determination of maximally immune-phenotype inducing combinations from these 17 strains is, however, experimentally infeasible as it would require the testing of 2^17^--1 = 131071 possible subsets in mice ([@bib12]). Therefore, a computational approach to prioritize which subsets to validate experimentally would have great utility. To our knowledge, to date there has been no model that allows for the simultaneous prediction of the dynamics of both the microbiota and the host immune response. Building on the approach to select for optimal bacterial combinations from ([@bib12]) and other efforts aimed at identifying potential immune-modulating microbes ([@bib16]; [@bib31]), we overcome this problem by proposing a mathematical modeling-based framework that, by resolving microbiome--immune system interactions with parameters constrained to experimental observations of microbiome and immune effectors, allows computational optimization of immune-stimulating bacterial combinations. To achieve this, we use a series of logically connected analyses that capture CD4^+^FOXP3^+^ T~reg~ accumulation in the colonic lamina propria ([@bib27]; [@bib29]) in response to the dynamics of human-derived Clostridia strains in germ-free mice, which had previously been shown to potently induce T~reg~ expansion ([@bib5]) ([Figure 1](#fig1){ref-type="fig"}). To constrain this proposed model framework to experimental data, we combine previously published ([@bib5]) and newly generated fluorescence-activated cell scanning (FACS) data with simulated and newly generated time-series colonization data from germ-free mice ([Figure 2A](#fig2){ref-type="fig"}). Subsequently, by applying a microbiome--T~reg~ mathematical model to this combined data set, we infer each strain's individual contribution to the CD4^+^FOXP3^+^ T~reg~ pool ([Figure 2B](#fig2){ref-type="fig"}) and obtain an estimate of every possible consortium's T~reg~ induction potential. To justify the usage of predicted mono-colonization concentrations from a previously developed microbiome ecological model ([@bib8]), we validate its ability in predicting temporal dynamics in response to different subsets of T~reg~-inducing strains ([Figure 3A](#fig3){ref-type="fig"}) and quantify the deviation of data and predictions ([Figure 3B](#fig3){ref-type="fig"}). Introduction of the TrIS, which assigns a score to every predicted steady-state microbial composition, enables us to identify combinations that robustly maximize T~reg~ induction ([Figure 4A](#fig4){ref-type="fig"}). We analyze the relationship of TrIS and biomass ([Figure 4B](#fig4){ref-type="fig"}) as well as metabolic features of the consortia ([Figure 4C and D](#fig4){ref-type="fig"}). Most importantly, we demonstrate the utility of our approach in predicting the potency of selected microbial combinations by validating the T~reg~ induction and colonization ability of model-predicted strong, intermediate and weak T~reg~-inducing consortia *in vivo* ([Figure 4E](#fig4){ref-type="fig"}).

![Conceptual figure.\
A microbiome--immune system mathematical model describing the activation of regulatory T-cells (T~reg~) in response to colonization profiles of T~reg~-stimulating Clostridia strains is the central element of this work. It consists of a previously derived microbiome ecological model that describes the short and long-term temporal dynamics of Clostridia strains in germ-free mice ([@bib8]) and is supplemented by a microbiome--T~reg~ model of CD4^+^FOXP3^+^ T~reg~ activation in response to long-term compositions in the microbiome. The individual contribution of each strain to the measured T~reg~ activation is inferred using long-term colonization data from mouse experiments with subsets of these strains and corresponding measurements of T~reg~ induction. The T~reg~-induction score, TrIS, which accounts for ecological stability and immune activation, assigns a score to every possible strain combination and thereby identifies candidate probiotic consortia for experimental validation.](elife-30916-fig1){#fig1}

![Data used for inference of the CD4^+^FOXP3^+^T~reg~ induction parameters.\
(**A**) To infer the strain-resolved CD4^+^FOXP3^+^ T~reg~ induction parameters CD4^+^FOXP3^+^ T~reg~ abundance measurements and corresponding microbiome colonization data are used. CD4^+^FOXP3^+^ T~reg~ data of single strains originates from previously published measurements from [@bib5]. Because in [@bib5] microbial mono-colonization levels were not measured, a previously published predictive model ([@bib8]) was used to simulate these experiments. In addition, newly generated CD4^+^FOXP3^+^ T~reg~ and colonization mouse stool data from three 11-strain combinations was included into the analysis (see also [Figure 3](#fig3){ref-type="fig"}). The 11-strain combinations were chosen according to results of the 'keystoneness' analysis previously described in [@bib8]. The microbiome compositions of these three 11-strain combinations were estimated by strain-specific qPCR. (**B**) The resulting CD4^+^FOXP3^+^ T~reg~ induction parameters quantify the contribution of each individual strain to T~reg~ induction. (Coefficients are scaled by the microbial mono-colonization concentrations for display reasons.)\
10.7554/eLife.30916.005Figure 2---source data 1.Data containing the microbiome compositions, the corresponding measured CD4^+^FOXP3^+^ proportions and the derived induction parameters.](elife-30916-fig2){#fig2}

![Validation of microbiome model describing the dynamics of Clostridia strains in germ-free mice.\
(**A**) The model-predicted dynamics of three 11-strain combinations from the 13 Clostridia strains described in [@bib8] (areas) are compared to measured data from germ-free mice (stacked bars) and each panel corresponds to an individual mouse ([Figure 2A](#fig2){ref-type="fig"}). Predictions were obtained by numerically integrating the corresponding generalized Lotka--Volterra equations with parameters from [@bib8] using only each mouse's initial microbial composition. In timelines/mouse 1--5, Strain 15 is absent referring to 11-strain set I (five biological replicates); in timelines 6--9, Strain 4 is absent (11-strain set II; four biological replicates), and in timelines 10--14, Strain 29 is absent (11-strain set III; five biological replicates). Data were obtained by qPCR of genes specific to each strain. Densities are computed as averages of three technical replicates. The number of mice used in each condition was chosen consistently with previous experimental work ([@bib5]; [@bib8]) and combined with extensive *in silico* testing of the inference error as a function of sampling frequency and noise levels ([@bib8]). (**B**) Spearman's rank correlation coefficient between observed and predicted data was computed at different time points. All displayed coefficients have a p-value of less than 10^−16^.](elife-30916-fig3){#fig3}

![Identification and experimental validation of model-predicted T~reg~-stimulating consortia.\
(**A**) Predicted T~reg~ Induction Score (TrIS) in germ-free mice as a function of probiotic consortium size. Each data point represents one of the 2*^N^*−1 possible non-trivial consortia of size *N*. The five highest and lowest TrIS consortia of size seven are highlighted by violet and cyan filled dots, respectively, as well as, the 4-strain consortia used for experimental validation in subpanel E. (**B**) Distribution of the TrIS plotted against the total population density of each model-predicted consortium. This analysis shows a strong correlation (Spearman's Rank Correlation with coefficient 0.88 and p\<0.05) between TrIS and total microbial density. The color of each dot represents the abundance of Strain 27, which is predicted to strongly colonize in high-TrIS subsets. (**C**) Heatmap of consortium membership of the five highest and lowest TrIS-consortia of size seven and their predicted T~reg~ induction and estimated butyrate production using data from [@bib5]. (**D**) Estimation of potential SCFA output based on single-strain *in vivo* metabolic profiling from [@bib5]. The five highest TrIS consortia of size seven (from 4C) are predicted to have a significantly higher SCFA output relative to the five lowest ones. (**E**) Five 4-strain consortia were used for experimental validation: the two highest-ranked consortia (H1 and H2, respectively), the lowest-ranked consortium (L) and two intermediates (M1, M2). M1 and M2 were included because of interest in other disease areas. The experimentally introduced strains are listed next to each bar/consortium. Strains with numbers in black were detected by 16S rRNA sequencing in mouse stool samples, strains with numbers in gray were introduced but failed to colonize. A Pearson's correlation of 0.97 between the predicted TrIS and the average of each consortium's measured CD4^+^FOXP3^+^ T~reg~ percentage proves the ability of the TrIS-based selection to correctly recover the experimentally observed T~reg~ induction. (Pearson's correlation of all points has a value of 0.54.) Importantly, the H2 consortium displays an average increase in immune activity of 107% relative to the average germ-free mouse control. Eight biological replicates were used for GF, H1 and H2, five biological replicates were used for M1, M2 and three biological replicates were used for L. Replication and design of the validation experiment for T~reg~ induction assessment is consistent with work from us and others ([@bib5]; [@bib25]).\
10.7554/eLife.30916.010Figure 4---source data 1.TrIS, TrIS rank and predicted median steady-state concentrations of the selected microbial consortia from [Figure 4E](#fig4){ref-type="fig"}.](elife-30916-fig4){#fig4}

We envision that our framework, while in this study tailored to finding combinations ameliorating auto-inflammatory conditions, may also have direct relevance to other immune-system enhancing applications such as the optimal delivery of probiotic-based cancer immunotherapies ([@bib14]).

Results {#s2}
=======

Generation of multimodal microbiome--T~reg~ data set {#s2-1}
----------------------------------------------------

The goal of this study is to develop a mathematical modeling-based framework to rapidly and systematically select microbial consortia that maximize a desired immune outcome when introduced in a specific host microbial background. To achieve this, we combine (i) a microbiome ecological model that accurately describes the dynamics of these bacteria in the host with (ii) a microbiome--T~reg~ mathematical model that characterizes the contribution of every strain to the immune phenotype of interest given corresponding microbiome colonization data ([Figure 1](#fig1){ref-type="fig"}). For (i), we gathered newly produced quantitative polymerase chain reaction (qPCR) colonization data from gnotobiotic mice and combined it with a previously published microbiome ecological model of the dynamics of 12 T~reg~-inducing Clostridia strains that are part of an original consortium of 17 T~reg~-inducing strains discovered by some of us ([@bib5]) (see also [Table 1](#table1){ref-type="table"} for a breakdown of strains used in each study). In contrast to the original study of ([@bib8]), we included only 12 of the 13 strains used there because, based on the modeling and analysis of [@bib8], Strain 6 from the 13-strain set was predicted to not stably colonize in the presence of the other 12 strains. The published colonization data have been reported in our previous work ([@bib8]) and include time-series measurements of microbial abundances by qPCR under dietary perturbations. These are used to derive a predictive microbiome ecology model in gnotobiotic conditions based on an extension of the generalized Lotka--Volterra (gLV) equations ([@bib19]) as introduced in [@bib34]. For the newly generated dataset, we gavaged 14 mice with one of three possible 11-strain subsets from the 12-strain subset of original 13 strains ([Figure 2](#fig2){ref-type="fig"}) and used the derived stool measurements to validate the ability of our mathematical model in predicting unseen conditions. The three 11-strain subsets were chosen based on our 'keystoneness' definition, a measure describing the marginal predicted quantitative effect of removing each strain from the full community ([@bib8]). Specifically, we included two 11-strain combinations each missing one of the two highest keystoneness-scoring strains (VE202 Strain 15 and VE202 Strain 4) and one 11-strain combination which lacks the lowest keystoneness scoring strain (VE202 Strain 29). In analogy to [@bib8], each strain's density was profiled over time by qPCR with strain-specific primers (see Materials and methods). To resolve the contribution of each of these to T~reg~ induction for point (ii) we coupled the colonization data from fecal content with newly collected and published FACS measurements of the CD4^+^FOXP3^+^ T~reg~ population in the lamina propria of these mice ([Figure 2A](#fig2){ref-type="fig"}). As it is crucial to capture each strain's contribution alone and in combination with others, we also included CD4^+^FOXP3^+^ T~reg~ measurements from our previously published mono-colonization experiments ([@bib5]) ([Figure 2A](#fig2){ref-type="fig"}). Due to the fact that the single-strain mono-colonization concentrations were not measured in these experiments ([@bib5]), we simulated them using the microbiome ecological model and parameters from ([@bib8]). This choice was supported by the model\'s capability in predicting unseen validation data ([Figure 3A](#fig3){ref-type="fig"}). Spearman's rank-order correlation coefficient ranges from 0.92 to 0.98 (p-value\<10^−16^) between observations and predictions depending on the time point ([Figure 3B](#fig3){ref-type="fig"}).

10.7554/eLife.30916.011

###### List of strains used with respect to our previous published work.

The original publication ([@bib5]) reported on 17 immune-modulating bacteria. In [@bib8], a dynamical ecological model for 13 of the original 17 strains was presented. These 13 strains were selected because they do not harbor antibiotic resistance genes. For our study, we used a 12-strain subset of these 13 strains based on ecological stability considerations. Colonization and CD4^+^FOXP3^+^T~reg~ data for the three 11-strain sets, measured by qPCR and FACS, were used along with the simulated mono-colonization concentrations ([Figure 2](#fig2){ref-type="fig"}) and included into the microbiome--immune system model ([Figure 1](#fig1){ref-type="fig"}). The resulting parameters were employed to predict ecologically stable subsets with different T~reg~ induction potentials. 4-strain subsets were selected to validate the predictions of the mathematical model (see main text and [Figure 3](#fig3){ref-type="fig"}). Strain 1: *Clostridium saccharogumia*/*Clostridium ramosum* JCM1298, Strain 3: *Flavonibacter plautii*/*Pseudoflavonifractor capillosus*, Strain 4: *Clostridium hathewayi*/*Clostridium saccharolyticum* WM1, Strain 6: *Blautia coccoides*/*Lachnospiraceae bacterium*, Strain 7: *Clostridium bolteae*, Strain 8: *Clostridium sp.* MLG055/*Erysipelotrichaceae bacterium* 2 44A, Strain 9: *Clostridium indolis*/*Anaerostipes caccae* DSM 14662, Strain 13: *Anaerotruncus colihominis*, Strain 14: *Ruminococcus sp.* ID8/*Lachnospiraceae bacterium* 2 1 46FAA, Strain 15: *Clostridium asparagiforme*/*Clostridium lavalense*, Strain 16: *Clostridium symbiosum*, Strain 18: *Clostridium ramosum*, Strain 21: *Eubacterium fissicatena*/*Eubacterium contortum*/*Clostridium sp.* D5, Strain 26: *Clostridium scindens*/*Lachnospiraceae bacterium* 5 1 57FAA, Strain 27: *Lacnospiraceae bacterium* A4/*Lachno bacterium* 3 1 57FAA CT1, Strain 28: *Clostridium sp.* 316002/08, Strain 29: *Lacnospiraceae bacterium* A4/*Lachno bacterium* 3 1 57FAA CT1.

              [@bib5]   [@bib8]   11-str. I   11-str. II   11-str. III   H1   H2   M1   M2   L   
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  Strain 1    x                                                                              
  Strain 3    x                                                                              
  Strain 4    x         x         x                        x                  x    x         
  Strain 6    x         x                                                                    
  Strain 7    x         x         x           x            x             x    x    x         
  Strain 8    x                                                                              
  Strain 9    x         x         x           x            x                            x    
  Strain 13   x         x         x           x            x                                 
  Strain 14   x         x         x           x            x                       x         x   
  Strain 15   x         x                     x            x                                 x   
  Strain 16   x         x         x           x            x                            x    x   
  Strain 18   x                                                                              
  Strain 21   x         x         x           x            x                                 
  Strain 26   x         x         x           x            x                                 
  Strain 27   x         x         x           x            x             x    x         x    
  Strain 28   x         x         x           x            x             x         x         
  Strain 29   x         x         x           x                          x    x         x    x   

Derivation of the microbiome--T~reg~ mathematical model {#s2-2}
-------------------------------------------------------

We used the described microbiome colonization data and corresponding CD4^+^FOXP3^+^ T~reg~ measurements to determine the contribution of each strain to the T~reg~ pool. We begin by subdividing the population of CD4^+^ T-cells into two major subpopulations depending on their intracellular FOXP3 expression: CD4^+^FOXP3^+^ T~reg~ and the remainder among the CD4^+^ T-cells, the conventional CD4^+^FOXP3^−^ T-cells ([@bib7]; [@bib30]). The concentration of CD4^+^ T-cells at time $t$ in the colonic lamina propria, $c_{\text{T}}(t)$, is then the combination of these two T-cell populations, $c_{\text{T}}\left( t \right) = c_{\text{FOXP}3^{+}}\left( t \right) + c_{\text{FOXP}3^{-}}\left( t \right)$. To include a variety of effects into our model, we assume T-cell dynamics to follow the gLV equations ([@bib15]; [@bib19]), which also account for the effect of the microbial strains in the lumen on the CD4^+^FOXP3^−^ T-cell subpopulation. In addition, we use an extension of the standard gLV equations to include the impact of the Clostridia strains in terms of external perturbations ([@bib34]). The resulting microbiome--T~reg~ mathematical model is found as,$$\begin{matrix}
{\frac{\text{d}c_{\text{FOXP}3^{+}}(t)}{\text{d}t} = c_{\text{FOXP}3^{+}}(t)\left( {\alpha_{\text{FOXP}3^{+}} + \beta_{\text{FOXP}3^{+}\text{FOXP}3^{+}}c_{\text{FOXP}3^{+}}(t)\phantom{\sum\limits_{k = 1}^{K}}} \right.} \\
\left. {+ \beta_{\text{FOXP}3^{+}\text{FOXP}3^{-}}c_{\text{FOXP}3^{-}}(t) + \sum\limits_{k = 1}^{K}\varepsilon_{i_{k}}c_{\text{strain}_{i_{k}}}(t)} \right) \\
\end{matrix}$$where $\alpha_{{\text{FOXP}3}^{+}}$ denotes the basal growth rate and $\beta_{{\text{FOXP}3}^{+}{\text{FOXP}3}^{+}}$ the self-interaction term of the CD4^+^FOXP3^+^ T~reg~ population. The interaction terms $\beta_{{\text{FOXP}3}^{+}{\text{FOXP}3}^{-}}$ and $\beta_{{\text{FOXP}3}^{-}{\text{FOXP}3}^{+}}$ represent the effect of the CD4^+^FOXP3^−^ T-cell on the CD4^+^FOXP3^+^ T~reg~ population and of the CD4^+^FOXP3^+^ T~reg~﻿ on the CD4^+^FOXP3^−^ T-cell population, respectively ([@bib10]). Consequently, positive interaction parameters correspond to activation, negative ones to inhibition. Moreover, $\varepsilon_{i_{k}}$ denotes the effect of strain $i_{k}$ on the CD4^+^FOXP3^+^ T~reg~ population. For long-term observations, $\left. t\rightarrow\infty \right.$, the dynamics of $\ c_{\text{FOXP}3^{+}}(t)$ are given by its (non-trivial) steady-state solution, which simplifies the then static microbiome--T~reg~ mathematical model of the relative CD4^+^FOXP3^+^ proportion in steady state, $r_{{\text{FOXP}3}^{+}\text{,}\text{ss}}$, to a linear regression problem,$$r_{\text{FOXP}3^{+}\text{,}\,\text{ss}} = \overset{\sim}{\alpha} + \sum\limits_{k = 1}^{K}{\overset{\sim}{\varepsilon}}_{i_{k}}c_{\text{strain}_{i_{k}\text{,}\,\text{ss}}}.$$

Here, we use that the absolute and relative abundance of the CD4^+^FOXP3^+^T~reg~ population are coupled by $\ c_{\text{FOXP}3^{+ / -}\text{,}\,\text{ss}} = c_{\text{T},\,\text{ss}} \cdot r_{FOXP3^{+ / -}\text{,}\,\text{ss}}$ (see Materials and methods). We assume that the steady-state CD4^+^ T-cell concentration is constant, $c_{\text{T,}\,\text{ss}} = \text{const.}$, across all microbial compositions. We justify this because we are dealing with genetically similar mice and a set of closely related Clostridia. This assumption is however not justifiable when comparing non-colonized and colonized germ-free mice ([@bib12]).

Assigning to $r_{\text{FOXP}3^{+}\text{,}\,\text{ss}}$ the measured FACS-derived CD4^+^FOXP3^+^ T~reg~ proportions after 35 days and to $c_{\text{strain}_{i_{k}}\text{,}\,\text{ss}}$ the corresponding microbial profiles, we infer each strain\'s contribution to the CD4^+^FOXP3^+^ T~reg~ pool ([Figure 2B](#fig2){ref-type="fig"}) by solving [Equation (2)](#equ2){ref-type="disp-formula"} with an $\ell^{2}$-penalized least-square regression with one shrinkage parameter, which is determined in a leave-one-sample-out cross-validation ([@bib34]). The resulting normalized root-mean square deviation on left-out samples was found to be 12%.

Derivation of the T~reg~ Induction Score (TrIS) and selection of T~reg~-inducing consortia {#s2-3}
------------------------------------------------------------------------------------------

After deriving a model to predict our candidate strains dynamics in germ-free conditions and having resolved each strain's contribution to T~reg~ expansion, we aim to use this information to computationally select for consortia that maximize T~reg~ induction while being ecologically robust ([@bib8]; [@bib34]). To specify a measure of ecological robustness as well as immune induction potential for microbial consortia in germ-free mice, we define the T~reg~ Induction Score (TrIS) as the average predicted regulatory T-cell activation of a given consortium of *K* strains $\left\{ {\text{strain}_{i_{1}},\cdots,\text{strain}_{i_{K}}} \right\}$ while ignoring contributions from the host,$$\text{TrIS}\left( \left\{ {\text{strain}_{i_{1}},\cdots,\text{strain}_{i_{K}}} \right\} \right)\text{=}\frac{1}{N}\sum\limits_{n = 1}^{N}\sum\limits_{k = 1}^{K}{\overset{\sim}{\varepsilon}}_{i_{k}}c_{\text{strain}_{i_{k}}\text{,}\,\text{ss}}^{(n)}.$$

If the predicted steady state of the microbial consortium $\left( {c_{\text{strain}_{i_{1}}}^{(n)},\ldots,c_{\text{strain}_{i_{K}}}^{(n)}} \right)_{\text{ss}}$ that is computed from the $n$-th Markov Chain Monte Carlo (MCMC) parameter estimate ([@bib8]) is biologically meaningful, i.e. positive, and stable, then $c_{\text{strain}_{i_{k}}\text{,}\,\text{ss}}^{(n)}$ denotes the steady-state concentration of strain $i_{k}$; otherwise $c_{\text{strain}_{i_{k}}\text{,}\,\text{ss}}^{(n)}$ is set to 0. Hence, the value of the TrIS is indicative of the expected CD4^+^FOXP3^+^ T~reg~ induction (after removing the host contribution) and it is of the same unit as the FACS measurements. We evaluated TrIS for every possible strain combination that would stably colonize the gut in germ-free background. In our computation, of the 2^12^--1 = 4095 possible steady-state strain configurations evaluated in *N* = 22,500 MCMC parameter estimates, 84% are found to be biologically meaningful and stable. Interestingly, while the average TrIS increases with consortium size, our analysis shows that a subset size of seven already contains bacterial combinations maximizing induction ([Figure 4A](#fig4){ref-type="fig"}). Furthermore, in addition to the strong correlation between TrIS and the predicted total bacterial abundance in the consortium, we observed that high-induction consortia display an especially large enrichment in the abundance of Strain 27 ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Because short-chain fatty acids have been previously associated with colonic T~reg~ induction ([@bib1]) and increase in density upon supplementation with these strains ([@bib5]), we decided to test if modeling-predicted high T~reg~-inducing consortia were also enriched in SCFAs. We therefore compared the top 5-inducing microbial consortia of size seven against their same-size counterpart bottom 5 ([Figure 4C](#fig4){ref-type="fig"}). We predicted the SCFA concentration for each of the predicted compositions by summing the scaled metabolic outputs of each strain measured in mono-colonization experiments ([@bib5]; [@bib25]) and normalized by the strain's model-predicted mono-colonization density. We performed a Welch two-samples t-test for each of the predicted SCFAs concentrations and found significant enrichment for all estimated SCFAs (p\<0.05, one tailed) in the high-TrIS consortia compared to the low ones ([Figure 4D](#fig4){ref-type="fig"}).

Experimental validation of mathematical model predictions {#s2-4}
---------------------------------------------------------

We decided to experimentally test our approach\'s ability to correctly predict consortium ranking with respect to T~reg~-induction. Due to regulatory constraints on the used probiotic strains -- limiting us to a maximum of four strains at a time in follow-up experiments -- we selected five 4-strain combinations with a variety of predicted immune effects. We measured CD4^+^FOXP3^+^ T~reg~ induction for five microbial consortia of size four and the germ-free control. We chose the two highest TrIS consortia (H1, H2 with rank 1 and 2, respectively), the lowest one (L with rank 495) and two TrIS-intermediate consortia of interest (M1, M2 with rank 129 and 452, respectively). Strains contained in each of the five consortia are detailed in [Table 1](#table1){ref-type="table"}. We correlated the TrIS score with the mean observed CD4^+^FOXP3^+^ T~reg~ percentage and found a significant Pearson correlation with coefficient of 0.97 and p-value\<0.01 ([Figure 4E](#fig4){ref-type="fig"}). Importantly, when using 16S rRNA sequencing to investigate the resulting colonization profiles for these combinations, we observed that the high TrIS-scoring consortia (H1, H2, M1) all stably colonized while the two low-scoring consortia only displayed a subset of the introduced strains. This result remarkably reflects the nature of our scoring system which, in addition to immune activation potential, also incorporates colonization success ([Equation 3](#equ3){ref-type="disp-formula"}).

Because the SCFA enrichment analysis from *in vivo* measurements of individual strains ([Figure 4C](#fig4){ref-type="fig"}) predicted acetate to be significantly increased in the five high versus low T~reg~-inducing consortia of size seven, we decided to compare the measured acetic acid concentrations ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}) to predictions of acetate in the two high (H1 and H2) and low (L) T~reg~-inducing 4-strain consortia ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). ANOVA and subsequent post-hoc Tukey test showed significance in the measured enrichment of H1 compared to L (adjusted p-value\<0.05) and of H1 compared to H2 (adjusted p-value\<0.05) ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). However, no statistical difference was observed between measurements in H2 and L (adjusted p-value\<0.05). Remarkably, the model-predicted germ-free normalized acetate enrichment and the observed acetic acid concentration (normalized by the mean in germ-free conditions) are well correlated ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}).

Discussion {#s3}
==========

Manipulation of the intestinal microbiota with defined bacterial consortia for the treatment of disease is a promising route for future therapeutics ([@bib18]). However, choosing bacterial combinations from the vast combinatorial space of microbes that effectively colonize a host (possibly with a dysbiotic microbiota) and at the same time maximize a desired host phenotype requires an enormous number of expensive and time-consuming experimental trials ([@bib12]). While data mining and statistical approaches could aid in this process, the majority of available microbiome analysis methods is still based on correlations ([@bib15]; [@bib24]) and inept at predicting unseen phenotypes. Identification of causal associations between microbes and host phenotype has been recently achieved by using an experimentally based microbe--phenotype triangulation ([@bib35]). However, this approach remains impractical when the goal is to explore and rank all possible microbiome consortium combinations with respect to a host phenotype of interest. In this study, we leveraged our previous computational methods to forecast temporal microbiome dynamics and make predictions on stability in the context of infectious and inflammatory diseases including *C. difficile* colonization and inflammatory bowel disease ([@bib8]; [@bib9]; [@bib34]). 

Specifically, we have presented a novel modeling-based method that combines dynamical predictions from data-driven models of the microbiome and the interactions between microbes and the immune response (such as CD4^+^FOXP3^+^ T~reg~) and thereby enables the rational design of immune-modulating bacterial consortia. Limiting our scope to long-term steady-state dynamics, we were able to derive a microbiome--T~reg~ mathematical model which is constrained by experimental observations from multimodal data. In the presented work, the used data modalities are qPCR and 16S rRNA sequencing data to estimate microbial abundances and FACS to assess CD4^+^FOXP3^+^ T~reg~ induction, respectively. However, the proposed framework is naturally extensible to other host data, for example data from metabolite profiling, immune readouts (e.g. CD8 T-cell activation, T~h~1/T~h~17 cell depletion) or host transcriptome profiling ([@bib3]; [@bib24]). To evaluate candidate consortia that could be relevant to the treatment of auto-inflammatory diseases, we introduced the T~reg~ Induction Score, TrIS, as a novel metric that accounts for both ecological stability and efficacy in immune modulation. This metric allowed us to rationally identify combinations that would stably colonize and at the same time produce substantial T~reg~ induction in germ-free mice. Remarkably, in validation experiments of five distinct modeling-guided consortia with predicted diverse induction potential, we proved the ability of our approach to successfully select microbial combinations with a desired therapeutic activity. To our knowledge, this is to date, the first study in which observation-constrained *in silico* modeling of microbiome and host phenotype has successfully guided the rational design of drugs of defined bacterial consortia.

Our work relies on the gLV model assumption for both microbiome and CD4^+^ regulatory T-cell dynamics which, despite being very versatile, has some limitations including the lack of third or higher order interactions or saturation effects ([@bib40]). Moreover, with the data available to us, we needed to assume that the overall T-cell density at steady state is constant across mice and different microbiome compositions. While this assumption was reasonable for the data we analyzed (see Results), the addition of future measurements on total T-cell abundance will likely improve the prediction accuracy of our model as well as provide important insight into the variability of T-cell population size in response to microbial immune induction.

We performed our data and modeling analysis in germ-free mice. While previous work by some of us showed that the amount of T~reg~ induction is independent of the germ-free background (IQI, Balb/c or C57BL/6) ([@bib4]), it is noteworthy that our model, which was trained on IQI mice data, robustly predicted both T~reg~ induction and acetate enrichment of C57BL/6 colonized mice as used in the validation experiments.

Our predictions suggest some degree of consistency in terms of functional outcome (e.g. enrichment in acetate) of high-scoring consortia relative to low-scoring ones in germ-free mice. However, before translating these findings into therapeutic development, future studies will need to be performed in not germ-free settings (e.g. SPF mice, humanized mice) in order to account for the effects of an already-established flora. Individual-specific microbiome features may constrain the colonization potential of the selected strains due to specific ecological network effects ([@bib33]), which suggests the need for a careful characterization of the ecological interactions between the proposed probiotic product and a specific recipient community (e.g. a single ulcerative colitis patient ([@bib5])).

Treatment of auto-immune diseases overall is not necessarily achieved by the exclusive optimization of one objective function (e.g. for ulcerative colitis, the maximization of T~reg~ activation), but may need the simultaneous manipulation of a multi-process host immune spectrum, which could include the concomitant reduction of pro-inflammatory phenotypes ([@bib4]). Given new data availability and careful experimental design, we believe that the modeling framework proposed in this study could overcome these problems by introducing constraints into the scoring metric that account for pre-colonized mouse model features. To the limit, in the presence of a large training data set that would include sufficient information on individual patient variation, our workflow will give us the unprecedented potential of testing microbiota manipulation on a personalized level *in silico*.

Mathematical modeling-based methods have the potential to greatly accelerate the development of treatment of human disease ([@bib23]). In this work, we develop and demonstrate in a first-of-a-kind experimental validation the usefulness of a mathematical microbiome--immune system model. It can be considered a stepping-stone to the accelerated prototyping and rational design of microbiome therapies.

Materials and methods {#s4}
=====================

Derivation of the microbiome--T~reg~ induction mathematical model {#s4-1}
-----------------------------------------------------------------

We assume the following dynamics for the CD4^+^FOXP3^+^ regulatory T-cell population:$$\begin{matrix}
{\frac{\text{d}c_{\text{FOXP}3^{+}}\left( t \right)}{\text{d}t} = c_{\text{FOXP}3^{+}}\left( t \right)} & {\left( {\alpha_{\text{FOXP}3^{+}} + \beta_{\text{FOXP}3^{+}\text{FOXP}3^{+}}c_{\text{FOXP}3^{+}}\left( t \right) + \ \beta_{\text{FOXP}3^{+}\text{FOXP}3^{-}}c_{\text{FOXP}3^{-}}\left( t \right) + \sum\limits_{k = 1}^{K}\varepsilon_{i_{k}}c_{\text{strain}_{i_{k}}}\left( t \right)} \right).} \\
\end{matrix}$$

Here, $\alpha_{{\text{FOXP}3}^{+}}$ denotes the basal growth rate and $\beta_{{\text{FOXP}3}^{+}{\text{FOXP}3}^{+}}$ the self-interaction term of the CD4^+^FOXP3^+^ T~reg~ population, while the interaction parameters $\beta_{{\text{FOXP}3}^{+}{\text{FOXP}3}^{-}}$ and $\beta_{{\text{FOXP}3}^{-}{\text{FOXP}3}^{+}}$ characterize the effect of the CD4^+^FOXP3^− ^T-cells on the CD4^+^FOXP3^+^ T~reg~ population and of the CD4^+^FOXP3^+ ^T~reg~ on the CD4^+^FOXP3^−^ T-cell population, respectively ([@bib10]). Moreover, $\varepsilon_{i_{k}}$ denotes the effect of strain $i_{k}$ on the CD4^+^FOXP3^+^ T~reg~ population. The non-trivial steady-state solution (i.e., the algebraic solution of the right-hand side of [Equation (1)](#equ1){ref-type="disp-formula"} set to 0 with $c_{{\text{FOXP}3}^{+}} \neq 0$) is found as,$$\begin{matrix}
{c_{\text{FOXP}3^{+}\text{,}\,\text{ss}}\!\!\!} & {= - \frac{1}{\beta_{\text{FOXP}3^{+}\text{FOXP}3^{+}}}\left( {\alpha_{\text{FOXP}3^{+}} + \beta_{\text{FOXP}3^{+}\text{FOXP}3^{-}}c_{\text{FOXP}3^{-}\text{,~ss}} + \sum\limits_{k = 1}^{K}\varepsilon_{i_{k}}c_{\text{strain}_{i_{k}\text{,}\,\text{ss}}}} \right).} \\
\end{matrix}$$

Using $c_{\text{T,}\,\text{ss}} = c_{\text{FOXP}3^{+}\text{,}\,\text{ss}} + c_{\text{FOXP}3^{-}\text{,}\,\text{ss}},$ the steady-state concentrations of the CD4^+^FOXP3^+^ T~reg~ and CD4+FOXP3^−^ populations, $c_{\text{FOXP}3^{+ / -}\text{,}\,\text{ss}}$, are derived from the FACS-based relative abundances $r_{\text{FOXP}3^{+ / -}\text{,}\,\text{ss}}$ by, $\ c_{\text{FOXP}3^{+ / -}\text{,}\,\text{ss}} = \ c_{T\text{,}\,\text{ss}} \cdot r_{FOXP3^{+ / -}\text{,}\ \text{ss}} = c_{\text{T,}\,\text{ss}}\left( {1 - r_{FOXP3^{- / +}\text{,}\,\text{ss}}} \right)$. Finally, the linear relationship between the relative abundances, $r_{\text{FOXP}3^{+}\text{,}\,\text{ss}}$, and the strain densities, $c_{\text{strain}_{i_{k}\text{,}\,\text{ss}}}$, is found as,$$\begin{matrix}
r_{\text{FOXP}3^{+}\text{,}\,\text{ss}} & {= \frac{1}{\beta_{\text{FOXP}3^{+}\text{FOXP}3^{-}} - \beta_{\text{FOXP}3^{+}\text{FOXP}3^{+}}}\left( {\frac{\alpha_{\text{FOXP}3^{+}}}{c_{\text{T,}\,\text{ss}}} + \beta_{\text{FOXP}3^{+}\text{FOXP}3^{-}} + \frac{1}{c_{\text{T,}\,\text{ss}}}\sum\limits_{k = 1}^{K}\varepsilon_{i_{k}}c_{\text{strain}_{i_{k}\text{,}\,\text{ss}}}} \right)} \\
 & {\equiv \overset{\sim}{\alpha} + \sum\limits_{k = 1}^{K}{\overset{\sim}{\varepsilon}}_{i_{k}}c_{\text{strain}_{i_{k}\text{,}\,\text{ss}}}} \\
\end{matrix}$$assuming constant concentration of CD4^+^ T-cells, $c_{\text{T,}\,\text{ss}} = \text{const}.$, across all possible microbiome compositions. The unknown parameters $\overset{\sim}{\alpha}$ and ${\overset{\sim}{\varepsilon}}_{i_{k}}$ are estimated in an $\ell^{2}$-penalized least-square regression (so-called ridge regression) with a positive shrinkage parameter $\lambda$, which is determined in a leave-one-sample-out cross-validation as $\lambda^{*} = 2$.

Collection of experimental data for training the microbiome--immune system model {#s4-2}
--------------------------------------------------------------------------------

### Strain abundance profiling {#s4-2-1}

In our previous work ([@bib8]), we have inferred a mathematical model describing the dynamics of a 13-strain subset from the original 17-strain human-derived Clostridia consortium from [@bib5] in germ-free mice. Using newly generated data from the same experimental setup, we are now able to assess its predictive quality for three distinct 11-strain subsets. The three 11-strain compositions were selected based on their capability to maintain stability in the simulations when either one of two high (Strain 15 and Strain 4, here referred to as cases I and II, respectively) or one low (Strain 29; III) keystone strain was removed ([@bib8]). For the experimental validation, germ-free IQI mice were purchased from Sankyo Laboratories (Japan), randomized and maintained in germ-free vinyl isolators in the animal facility of RIKEN. Twelve T~reg~-inducing Clostridia strains were selected from the previously reported VE202 consortium consisting of 17 T~reg~-inducing strains (4, 7, 9, 13--16, 21, 26--29) and were individually cultured in modified Eggerth Gagnon broth under strictly anaerobic conditions (80% N~2~, 10% H~2~, 10% CO~2~) at 37°C in an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI) to confluence. The cultured bacterial strains were then mixed and the three mixtures of 11 strains (described above) were orally inoculated into five IQI germ-free adult mice each. One mouse for condition II died and was therefore discarded from the study. After an initial 9-day interval of acclimation, we collected fecal pellets at 2--4 days interval until day 35, time at which mice were euthanized and analyzed for CD4^+^FOXP3 induction as in [@bib5]). Colonization levels for each strain were assessed by amplifying strain-specific regions with qPCR as described in [@bib8]. Bacterial genomic DNA was extracted from 1 to 2 fecal pellets using QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). The amount of DNA was quantified using a Qubit dsDNA HS assay kit and Qubit fluorometer (Invitrogen, Carlsbad, CA). DNA was then subjected to qPCR using Thunderbird SYBR qPCR Mix (TOYOBO, Osaka, Japan) and a LightCycler 480 (Roche) with primers specific to 16S ribosomal RNA (rRNA) genes of the 12 Clostridia strains as in [@bib8]. Quantification of each strain in each sample was accomplished using standard curves of known concentrations of DNAs purified from each strain individually cultured *in vitro*. Strain densities in each sample were calculated by dividing the above absolute quantification numbers by the weight of the extracted fecal DNA. The 11-strain experiments were ethically approved by RIKEN, Keio and Azabu Universities under protocol H24-9(14) from RIKEN.

Estimation of CD4^+^FOXP3^+^ T~reg~ -- Isolation of intestinal lamina propria lymphocytes and flow cytometry {#s4-3}
------------------------------------------------------------------------------------------------------------

The colons were collected and opened longitudinally, washed with PBS to remove all luminal contents and shaken in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37°C. After removing epithelial cells, muscle layers and fat tissue using forceps, the lamina propria layers were cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum, 0.5 mg/ml collagenase D, 0.5 mg/ml dispase and 40 mg/ml DNase I (all Roche Diagnostics, Risch-Rotkreuz, Switzerland) for 1 hr at 37°C in a shaking water bath. The digested tissues were washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (GE Healthcare, Boston, MA) and overlaid on 2.5 ml of 80% Percoll in a 15 ml Falcon tube. Percoll gradient separation was performed by centrifugation at 850 *g* for 25 min at 25°C. The lamina propria lymphocytes were collected from the interface of the Percoll gradient and suspended in ice-cold PBS. For analysis of T~reg~, isolated lymphocytes were labeled with the LIVE/DEAD fixable dead cell stain kit (Life Technologies, Carlsbad, CA) to exclude dead cells from the analysis. Then, surface and intracellular staining of CD3, CD4 and FOXP3 was performed using the BV605-labeled anti-CD3 (17A2, Biolegend, San Diego, CA), BV421-labeled anti-CD4 (RM4-5, Biolegend), Alexa700-labeled anti-FOXP3 antibody (FJK-16 s, eBioscience, San Diego, CA), and FOXP3 staining buffer set (eBioscience). The antibody-stained cells were analyzed with LSR Fortessa and data were analyzed using FlowJo software (Tree Star, Ashland, OR).

Measurement of organic acids {#s4-4}
----------------------------

Organic acid concentrations in caecal contents were determined by gas chromatography-mass spectrometry (GC-MS). Caecal contents (10 mg) were disrupted using 3 mm zirconia/silica beads (BioSpec Products) and homogenized in extraction solution containing 100 ml of internal standard (100 mM crotonic acid), 50 ml of HCl and 200 ml of ether. After vigorous shaking using a Shakemaster neo (Bio Medical Science) at 1500 rpm for 10 min, homogenates were centrifuged at 1000 *g* for 10 min and then the top ether layer was collected and transferred into new glass vials. Aliquots (80 ml) of the ether extracts were mixed with 16 ml of N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA). The vials were sealed tightly by screwing and heated at 80°C for 20 min in a water bath, and left at room temperature for 48 hr for derivatization. The samples were then run through a 6890N Network GC System (Agilent Technologies) equipped with HP-5MS column (0.25 mm 330 m 30.25 mm) and 5973 Network Mass Selective Detector (Agilent Technologies, Santa Clara, CA). Pure helium (99.9999%) was used as a carrier gas and delivered at a flow rate of 1.2 ml/min. The head pressure was set at 10 psi with split 10:1. The inlet and transfer line temperatures were 250 µC and 260 µC, respectively. The following temperature program was used: 60 µC (3 min), 60--120°C (5°C/min), 120--300°C (20°C/min). One microliter quantity of each sample was injected with a run time of 30 min. Organic acid concentrations were quantified by comparing their peak areas with the standards.

Numerical simulations of the three 11-strain subsets used for microbiome--T~reg~ model training {#s4-5}
-----------------------------------------------------------------------------------------------

We used 22,500 sets of Markov Chain Monte Carlo generalized Lotka--Volterra parameter sets determined by applying the Bayesian Variable Selection algorithm within MDSINE to the data of [@bib8], and the first time point of measured microbial profiles for each of the 14 validation mice as initial condition, to simulate the gLV system of differential equations corresponding to each mouse microbiome ([Figure 3A](#fig3){ref-type="fig"}). Prediction accuracy was evaluated by calculating the Spearman correlation coefficient between observed and predicted data ([Figure 3B](#fig3){ref-type="fig"}).

Simulation of mono-colonization abundances {#s4-6}
------------------------------------------

As the experimental data from [@bib5] only provided CD4^+^FOXP3^+^ T-cell levels for the mono-strain colonization experiments at 35 days after inoculation but no measurement of the long-term microbial concentrations in the gut, we used instead the corresponding estimated mono-strain colonization densities obtained from the gLV model (section above and [Figure 2A](#fig2){ref-type="fig"}). In general, the long-term behavior of the gLV system is determined by its steady states which are uniquely defined by the inferred model parameters ([@bib34]). We computed the parameter median in each single model variable from the 22,500 MCMC parameter sets. These median parameters were then used to deduce the steady-state densities, which were together with the measured CD4^+^FOXP3 proportions included into the training of the microbiome--T~reg~ model.

Collection of CD4^+^FOXP3^+^ T~reg~ data from 4-strain experiments for validation of the modeling-based predictions {#s4-7}
-------------------------------------------------------------------------------------------------------------------

Bacterial strains 4, 7, 9, 14, 15, 16, 27, 28, 29 were grown anaerobically in PYG broth (Peptone, Yeast and Glucose broth from Anaerobe Systems, Cat no: AS-822) until they reached stationary phase (48 hr for strains 27 and 29, 24 hr for the remaining strains). Each 200 µl-mouse dose of a 4-strain LBP contained 50 µl of 20 times concentrated stationary phase culture. Germ-free C57BL/6 mice aged 6--8 weeks were randomized and gavaged with a total dose of 5·10^7^--2·10^8^ bacteria in a 200 µl, and maintained under gnotobiotic conditions for four weeks. Use of a C57BL/6 background for these experiments was motivated by availability of animals at the facility where we performed the validation and justified by the fact that previous work from us has shown that T~reg~ induction by our Clostridia strains does not differ between Balb/c, IQI, and C57BL/6 mice ([@bib4]). Mice were then sacrificed, colons harvested, and lamina propria leukocytes isolated and stained for CD3^+^CD4^+^FOXP3^+^ T~reg~ as described above. Eight mice each were used for consortia High 1 (H1-strains: 7, 27, 28, 29) and High 2 (H2-strains: 4, 7, 27, 29). Five mice each were used for the intermediate high (M1-strains: 4, 7, 14, 28), and intermediate low consortia (M2-strains: 9, 16, 27, 29). Three mice were used for Low 1 (L1-strains: 14, 15, 16, 29). Colonization profiling was determined through 16S rRNA sequencing (as above) and verified by blasting representative sequences to a 16S VE202 fasta database. The 4-strain validation experiments were performed in the Massachusetts Host Microbiome Center under IACUC protocol 2016N000141.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Computational prediction of immune effectors from the microbiome to select for optimal immune--modulating consortia\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wendy Garrett as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors colonize germ--free mice with individual bacterial strains, and test for induction of T~regs~. They then use this information to construct a model for induction of T~regs~ by a complex microbial community, reducing the number of combinations that must be tested explicitly. Specifically, they predict strong-- and weak--inducing consortia and provide experimental validation of fit to the model. The authors use existing qPCR data from 13 strains and a generalized Lotka--Volterra model they previously published as the basis for the experimental validation. They deploy this model on 11--strain and 4--strain consortia. The three 11--strain combinations consist of two that lack strains with the highest \"keystone\" scores, and one that lacks the strain with the lowest score. They also test five 4--strain consortia, again collecting information on the dynamics. They also provide additional predictions relevant to ulcerative colitis.

In our view, this manuscript provides a fascinating example of validation of computational predictions relating specific microbial strains to immune response. However, we believe that although the work is impressive, additional validation needs to be done and that the last disease test case is less convincing than the rest of the work. We recommend that this be either removed or that experimental validation be provided.

Overall this is an impressive body of work and, as the authors note, point the way towards better rational design of microbial communities that alter the immune system.

Essential revisions:

1\) Several of the figures are misleading or unreadable. Figure 3 shows observed vs predicted data and r^2^ in log space, but the results are likely to look much worse in linear space given the pattern of scatter, and this should be disclosed to readers rather than concealed.

2\) Figure 4B is unreadable, and per--strain correlations should be summarized in a different way that is easier to understand.

3\) Figure 5A is also unreadable and it is impossible to match up the stacked bar and area presentation; some other form of showing the data is needed.

4\) Because the pathway data are normalized, Mann--Whitney U is not appropriate (in related tasks, its false discovery rate has been shown to be up to 95%) and appropriate statistics for differential abundance that take compositionality into account should be used.

5\) The theoretical predictions for the consortia transferred into mice with UC patient stool, while intriguing, should ideally be backed by experiment. The results showing model fit to data for the 4--strain communities are impressive but much weaker than the rhetoric in the text implies: Spearman rho of --0.47 means that more than three quarters of the variance in the rank order of the data, let alone the quantitative data, is not explained by their explanatory variable. So, although the association is statistically significant, its power to predict results is low. This component should be removed.

6\) The authors have only moderate support for their primary hypothesis: that immune response as a function of microbial consortia can be predicted via a model. In the GF mouse case, I see the key data testing this hypothesis in Figure 4E. While the stated correlation is significant, I\'m concerned this statistic is being used inappropriately. Incorporating the replicates into the correlation seems ill--advised (doing so, for example, could let you compute a correlation involving only two groups provided each had enough replicates within). Rather, if the authors want to use the replicates, an ANOVA with post--hoc tests seems more appropriate. Perhaps even better, the authors could correlate the mean observed percentage of CD4^+^FOXP3^+^ to the mean predicted TrIS across the 5 groups. The trends look promising. But, this may be too small a number of groups to actually power such a correlation; hence, my overall concern that there\'s not enough data validating the model.

7\) The manuscript needs to make clear when the authors are using new vs. previously published, and in silico vs. measured data. Examples include Figure 4, which analyses the in-silico results using a mixture of metabolomic predictions and experimental validation. It seems Figure 1 and Figure 2 are efforts to clear up that confusion. Unfortunately, they didn\'t work in my case; perhaps it's worth trying to merge those figures into a single flow chart?

8\) Some variables in Equations 1--3 aren\'t explicitly defined in the text (and don\'t seem to be in the Materials and methods section either), including i, α, β, ε, and n. These need to be defined.

9\) How many strains were available and how many strains were actually selected? The numbers mentioned in the text are inconsistent in different parts. I provide only a few examples below, but this inconsistency is present throughout the text.

-- Introduction: \"a mixture of 17 human--derived Clostridia (ref 9)\".

-- Introduction: \"our previous work identified on the order of 15 possible candidate strains to select from (ref 9)\".

-- Results section: \"we gavaged 14 mice with one of three possible 11--strain subsets from the original 13 strains (Figure 2)\".

-- Figure 1: \"12 therapeutically relevant Clostridia strains in the lumen\".

-- Figure 2: \"13 strain cocktail\".

Bottom line, the authors should provide a clear layout/table of the strains that were identified in ref 9, of the strains that were used in the paper, and of the combinations. At the moment, this part is very confusing, and the numbers do not match throughout the text.

10\) How many GF mice were actually used, and why do the authors use IQI GF mice for some experiments, and C57BL/6 GF mice for others? The mouse genetic background was changed for no apparent reason.

Also Introduction: \"we gavaged 14 mice with one of three possible 11--strain subsets from the original 13 strains (Figure 2)\".

Materials and methods section: \"the three mixtures of 11 strains (described above) were orally inoculated into five IQI germ--free adult mice each.\"

How many mice were actually gavages with the 11 strains? 14 or 5? Please clarify the experimental design.

10.7554/eLife.30916.017

Author response

> Essential revisions:
>
> 1\) Several of the figures are misleading or unreadable. Figure 3 shows observed vs predicted data and r^2^ in log space, but the results are likely to look much worse in linear space given the pattern of scatter, and this should be disclosed to readers rather than concealed.

We edited Figure 3 by removing the old scatter plot (old panel B) and substituted it with one where we calculated the Spearman correlation between observations and predictions at different discrete time points in order to not violate the assumption of independence of observations for correlation tests. Calculation of Spearman's correlation between predictions and observations follows our previous work (Stein et al., 2013). See also subsection "Generation of multimodal microbiome--T~reg~ data".

> 2\) Figure 4B is unreadable, and per--strain correlations should be summarized in a different way that is easier to understand.

We agree with the reviewer's comment. Accordingly, we modified Figure 4B to only focus on Strain 27. We added a new supplementary figure (Figure 4---figure supplement 1) to display the same analysis for all other strains each in a separate panel.

> 3\) Figure 5A is also unreadable and it is impossible to match up the stacked bar and area presentation; some other form of showing the data is needed

Following the suggestion from the editor we removed the UC biota analysis. Hence, Figure 5 is now removed from the manuscript.

> 4\) Because the pathway data are normalized, Mann--Whitney U is not appropriate (in related tasks, its false discovery rate has been shown to be up to 95%) and appropriate statistics for differential abundance that take compositionality into account should be used.

We agree with the reviewer's comment. Similarly to the response to comment \#3, this analysis is not anymore included as the UC-biota related work has been removed from the manuscript.

> 5\) The theoretical predictions for the consortia transferred into mice with UC patient stool, while intriguing, should ideally be backed by experiment. The results showing model fit to data for the 4--strain communities are impressive but much weaker than the rhetoric in the text implies: Spearman rho of --0.47 means that more than three quarters of the variance in the rank order of the data, let alone the quantitative data, is not explained by their explanatory variable. So, although the association is statistically significant, its power to predict results is low. This component should be removed.

As suggested by the editor, we removed the data and analysis pertaining the UC biota scenario. Regarding the analysis of the 4--strain validation experiments see the response to comment \#6.

> 6\) The authors have only moderate support for their primary hypothesis: that immune response as a function of microbial consortia can be predicted via a model. In the GF mouse case, I see the key data testing this hypothesis in Figure 4E. While the stated correlation is significant, I\'m concerned this statistic is being used inappropriately. Incorporating the replicates into the correlation seems ill--advised (doing so, for example, could let you compute a correlation involving only two groups provided each had enough replicates within). Rather, if the authors want to use the replicates, an ANOVA with post--hoc tests seems more appropriate. Perhaps even better, the authors could correlate the mean observed percentage of CD4^+^FOXP3^+^ to the mean predicted TrIS across the 5 groups. The trends look promising. But, this may be too small a number of groups to actually power such a correlation; hence, my overall concern that there\'s not enough data validating the model.

We fully agree with the reviewer's comment and followed the reviewer's suggestion to correlate the mean CD4^+^FOXP3^+^ Treg level for each consortium with the modeling-predicted Treg induction score. Pearson's correlation yields a coefficient of 0.97 and a p-value \< 0.01. This should sufficiently validate our modeling predictions. We accordingly modified the text (see subsection "Derivation of the Treg Induction Score (TrIS) and selection of T~reg~-inducing consortia"), the related figure panel and the corresponding caption.

> 7\) The manuscript needs to make clear when the authors are using new vs. previously published, and in silico vs. measured data. Examples include Figure 4, which analyses the in-silico results using a mixture of metabolomic predictions and experimental validation. It seems Figure 1 and Figure 2 are efforts to clear up that confusion. Unfortunately, they didn\'t work in my case; perhaps it's worth trying to merge those figures into a single flow chart?

We agree with the reviewer and apologize for the confusion. We edited Figure 1 to be solely a clear conceptual diagram detailing the entire workflow that we present in the paper. We also rearranged Figure 2 and explicitly state what is new data and what data was published already. Also, we now explicitly specify (in Figure 2 and caption) what data was experimentally measured and what was derived from in silico simulations. We also better describe this in the main text (see Introduction and Results section). See also response to comment \#9.

> 8\) Some variables in Equations 1--3 aren\'t explicitly defined in the text (and don\'t seem to be in the Materials and methods section either), including i, α, β, ε, and n. These need to be defined.

Following the reviewer's suggestion, we included a detailed description of the used parameters when they are introduced (see subsection "Derivation of the microbiome--T~reg~ mathematical model to select microbial consortia" and Discussion section).

> 9\) How many strains were available and how many strains were actually selected? The numbers mentioned in the text are inconsistent in different parts. I provide only a few examples below, but this inconsistency is present throughout the text.
>
> -- Introduction: \"a mixture of 17 human--derived Clostridia (ref 9)\".
>
> -- Introduction: \"our previous work identified on the order of 15 possible candidate strains to select from (ref 9)\".
>
> -- Results section: \"we gavaged 14 mice with one of three possible 11--strain subsets from the original 13 strains (Figure 2)\".
>
> -- Figure 1: \"12 therapeutically relevant Clostridia strains in the lumen\".
>
> -- Figure 2: \"13 strain cocktail\".
>
> Bottom line, the authors should provide a clear layout/table of the strains that were identified in ref 9, of the strains that were used in the paper, and of the combinations. At the moment, this part is very confusing, and the numbers do not match throughout the text.

We agree with the reviewer comment and again apologize for the confusion. Following the reviewers comment we made a table (Table 1) detailing membership for all the experiments performed for this work as well as from our previous studies. We also modified the text to clarify this point (Introduction).

> 10\) How many GF mice were actually used, and why do the authors use IQI GF mice for some experiments, and C57BL/6 GF mice for others? The mouse genetic background was changed for no apparent reason.
>
> Also Introduction: \"we gavaged 14 mice with one of three possible 11--strain subsets from the original 13 strains (Figure 2)\".
>
> Materials and methods section: \"the three mixtures of 11 strains (described above) were orally inoculated into five IQI germ--free adult mice each.\"
>
> How many mice were actually gavages with the 11 strains? 14 or 5? Please clarify the experimental design.

We made consistent and clarified in throughout text the number of animals used. The use of a C57BL/6 background for these experiments was motivated by animal availability at the time of performing experimental validation. C57BL/6 use can be justified by the fact that previous work from us has shown that Treg induction by our Clostridia strains does not differ between Balb/c, IQI, and C57BL/6 mice (see Atarashi et al., 2015). We reworded the text and this statement and added a paragraph to the Discussion section.

[^1]: These authors contributed equally to this work.
